NEW HAVEN, Conn. — October 7, 2026
Arvinas, Inc. presented new Phase 1 clinical data for ARV-102 in patients with Parkinson’s disease at the 2026 International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Seoul, South Korea. The late-breaking oral and poster presentations included oculomotor and biomarker findings from a clinical study evaluating ARV-102, an investigational orally bioavailable PROTAC designed to cross the blood-brain barrier and selectively degrade leucine-rich repeat kinase 2 (LRRK2). The findings showed dose-dependent changes in an objective measure of impaired eye movement associated with Parkinson’s disease, along with reductions in LRRK2 protein levels in cerebrospinal fluid (CSF) and changes in biomarkers associated with endolysosomal, neuroinflammatory and synaptic pathways. Arvinas said the findings support continued clinical evaluation of ARV-102 as a potential therapeutic approach for neurodegenerative diseases associated with LRRK2 dysregulation.
ARV-102 Shows Dose-Related Oculomotor Changes
The Phase 1 trial evaluated oral doses of ARV-102 ranging from 20 mg to 80 mg, as well as placebo, over 28 days in a total of 24 patients with Parkinson’s disease. One of the key findings was a dose-dependent increase in the amplitude of saccadic hypometria (ASH) after 28 days of treatment compared with placebo. Saccadic hypometria refers to reduced eye-movement amplitude and represents an objective measure of impaired oculomotor function associated with Parkinson’s disease. Arvinas said the observed changes reflected less severe hypometria following treatment. The company also reported associations between reductions in CSF LRRK2 protein levels and improvements in oculomotor function. Importantly, Arvinas emphasized that the Phase 1 study was not designed to establish clinical efficacy, making the oculomotor findings exploratory rather than evidence of therapeutic benefit. The data nevertheless provide an additional clinical measure for evaluating the biological effects of LRRK2 degradation in patients with Parkinson’s disease.
LRRK2 Degradation Linked to Multiple Biomarker Changes
In addition to the oculomotor findings, ARV-102 treatment was associated with changes in several CSF biomarkers linked to neurodegenerative disease pathways. Arvinas reported decreases in biomarkers associated with endolysosomal function and neuroinflammation, together with increases in biomarkers associated with synaptic integrity and axonal guidance. The company also identified associations between reductions in CSF LRRK2 levels and changes in these biological pathways. Earlier Phase 1 findings presented at AD/PD 2026 had demonstrated that ARV-102 reaches the central nervous system and reduces LRRK2-related endolysosomal and neuroinflammatory biomarkers in CSF. The latest MDS data add oculomotor measurements and further biomarker relationships to the emerging clinical profile of the investigational PROTAC. Together, the findings provide evidence that ARV-102 can engage its intended target in the brain and modulate biological pathways relevant to Parkinson’s disease, supporting additional clinical investigation of LRRK2 degradation.
Advertisement
Arvinas Advances ARV-102 Neurodegeneration Program
ARV-102 is designed to selectively degrade LRRK2, a multidomain protein with kinase and GTPase activity whose increased activity or expression has been implicated in Parkinson’s disease and other neurological disorders. Arvinas is developing the candidate using its PROTAC targeted protein degradation platform, with the objective of selectively removing disease-associated proteins rather than simply inhibiting their activity. The company is continuing to evaluate ARV-102 as a potential treatment approach for neurodegenerative diseases associated with LRRK2 dysregulation, including Parkinson’s disease. The MDS 2026 findings provide additional clinical evidence of central nervous system exposure, target degradation and biological pathway modulation while identifying an exploratory relationship between LRRK2 reduction and oculomotor function. Arvinas will use these findings to support the continued clinical development of ARV-102, while recognizing that additional studies will be needed to determine whether these biological and functional signals translate into meaningful clinical benefits for patients.
Source::Arvinas,, press release
